US Court rules in favor of Sanofi and Regeneron in ongoing Praluent patent litigation

29 August 2019

French pharma major Sanofi (Euronext: SAN) and partner Regeneron Pharmaceuticals (Nasdaq: REGN) yesterday announced that the US District Court for the District of Delaware ruled in their favor and found as a matter of law that US biotech firm Amgen’s (Nasdaq: AMGN) asserted patent claims for antibodies targeting PCSK9 (proprotein convertase subtilisin/kexin type 9) are invalid based on lack of enablement.

This decision overturns portions of a jury verdict reached in February that upheld the validity of three of five claims asserted by Amgen on two of its US patents for its PCSK9 inhibitor Repatha (evolocumab). Sanofi and Regeneron market the rival PCSK9 inhibitor Praluent (alirocumab). This means that Sanofi and Regeneron have successfully invalidated all five asserted Amgen patent claims, said Sanofi.

Regeneron’s shares closed up 2.21% at $287.64 in US trading on Wednesday, while Sanofi’s stock was up 1.08% at 78.32 euros in early Paris activity today.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK